These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37776482)

  • 1. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
    Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
    Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
    Tan Y; Buch MH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Characteristics of Adults with Difficult-to-Treat Rheumatoid Arthritis in a Large Patient Registry.
    Paudel ML; Li R; Naik C; Shadick N; Weinblatt ME; Solomon DH
    Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38837701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Aug; 60(8):3778-3788. PubMed ID: 33331946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.
    Qi W; Robert A; Singbo N; Ratelle L; Fortin PR; Bessette L; Brown JP; Michou L
    Adv Rheumatol; 2024 Aug; 64(1):55. PubMed ID: 39107865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; van Oorschot EPC; Nikiphorou E; Nijhof NC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM; Geenen R
    Rheumatology (Oxford); 2021 Nov; 60(11):5105-5116. PubMed ID: 33560301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease.
    Leon L; Madrid-Garcia A; Lopez-Viejo P; González-Álvaro I; Novella-Navarro M; Freites Nuñez D; Rosales Z; Fernandez-Gutierrez B; Abasolo L
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.
    Alp G; Cinakli H; Kurut Aysin İ; Solmaz D; Akar S
    Clin Exp Rheumatol; 2024 Jul; 42(7):1398-1406. PubMed ID: 38372714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
    Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
    Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PMJ; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Pchelnikova P; Blaas E; Senolt L; Szekanecz Z; Choy EH; Dougados M; Jacobs JW; Geenen R; Bijlsma JW; Zink A; Aletaha D; Schoneveld L; van Riel P; Dumas S; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2022 Jan; 81(1):20-33. PubMed ID: 34407926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
    Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients.
    Cincinelli G; Maioli G; Posio C; Favalli EG; Ingegnoli F; Caporali R
    Arthritis Res Ther; 2024 Sep; 26(1):161. PubMed ID: 39289770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of fatigue in difficult-to-treat rheumatoid arthritis.
    Leon L; Freites-Núñez D; Madrid A; Rodriguez-Mariblanca M; Fernandez-Gutierrez B; Abasolo L
    BMC Rheumatol; 2024 Sep; 8(1):49. PubMed ID: 39350299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
    Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis.
    Su QY; Luo J; Zhang Y; Li Q; Jiang ZQ; Wen ZR; Wang YY; Shi MR; Zhang SX
    J Transl Med; 2024 Aug; 22(1):795. PubMed ID: 39198829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems.
    Watanabe R; Okano T; Gon T; Yoshida N; Fukumoto K; Yamada S; Hashimoto M
    Front Med (Lausanne); 2022; 9():1049875. PubMed ID: 36353219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis.
    Guo H; Li L; Liu B; Lu P; Cao Z; Ji X; Li L; Ouyang G; Nie Z; Lyu A; Lu C
    Int Immunopharmacol; 2023 Sep; 122():110655. PubMed ID: 37481847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis.
    Philippoteaux C; Marty-Ane A; Cailliau E; Labreuche J; Philippe P; Cortet B; Paccou J; Flipo RM; Letarouilly JG
    Semin Arthritis Rheum; 2023 Dec; 63():152275. PubMed ID: 37852155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.